310 related articles for article (PubMed ID: 35450750)
1. Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.
Nakamura H; Kataoka Y; Nicholls SJ; Puri R; Kitahara S; Murai K; Sawada K; Matama H; Iwai T; Honda S; Fujino M; Takagi K; Yoneda S; Otsuka F; Nishihira K; Asaumi Y; Tsujita K; Noguchi T
Atherosclerosis; 2022 May; 349():183-189. PubMed ID: 35450750
[TBL] [Abstract][Full Text] [Related]
2. Sex Differences in the Density of Lipidic Plaque Materials: Insights From the REASSURE-NIRS MultiCenter Registry.
Kataoka Y; Nicholls SJ; Puri R; Kitahara S; Kiyoshige E; Nishimura K; Murai K; Iwai T; Sawada K; Matama H; Honda S; Takagi K; Fujino M; Yoneda S; Otsuka F; Nishihira K; Takamisawa I; Asaumi Y; Noguchi T
Circ Cardiovasc Imaging; 2023 May; 16(5):e015107. PubMed ID: 37161775
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
[TBL] [Abstract][Full Text] [Related]
4. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
[TBL] [Abstract][Full Text] [Related]
5. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
6. Case report: a potential modulation of coronary atheroma by lowering triglyceride-rich lipoproteins with pemafibrate: insights from serial near-infrared spectroscopy imaging.
Murata Y; Kataoka Y; Asaumi Y; Noguchi T
Cardiovasc Diagn Ther; 2023 Feb; 13(1):100-108. PubMed ID: 36864976
[TBL] [Abstract][Full Text] [Related]
7. The Residual Lipid-Rich Coronary Atheroma Behind the Implanted Newer-Generation Drug-Eluting Stent and Future Stent-Related Event Risks.
Murai K; Kataoka Y; Nicholls SJ; Puri R; Nakaoku Y; Nishimura K; Kitahara S; Iwai T; Sawada K; Matama H; Honda S; Fujino M; Yoneda S; Takagi K; Nishihira K; Otsuka F; Asaumi Y; Tsujita K; Noguchi T
Can J Cardiol; 2022 Oct; 38(10):1504-1515. PubMed ID: 35840020
[TBL] [Abstract][Full Text] [Related]
8. The association between circulating lipoprotein subfractions and lipid content in coronary atheromatous plaques assessed by near-infrared spectroscopy.
Sæther JC; Vesterbekkmo EK; Gigante B; Giskeødegård GF; Bathen TF; Follestad T; Wiseth R; Madssen E; Bye A
Int J Cardiol Heart Vasc; 2023 Jun; 46():101215. PubMed ID: 37255857
[TBL] [Abstract][Full Text] [Related]
9. Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.
Kataoka Y; Hammadah M; Puri R; Duggal B; Uno K; Kapadia SR; Murat Tuzcu E; Nissen SE; Nicholls SJ
Atherosclerosis; 2015 Oct; 242(2):490-5. PubMed ID: 26298740
[TBL] [Abstract][Full Text] [Related]
10. Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy.
Matsushita K; Hibi K; Komura N; Kimura Y; Matsuzawa Y; Konishi M; Maejima N; Iwahashi N; Kosuge M; Ebina T; Tamura K; Kimura K
J Cardiol; 2020 Jul; 76(1):66-72. PubMed ID: 32037254
[TBL] [Abstract][Full Text] [Related]
11. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
12. Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.
Chieng D; Pang J; Ellis KL; Hillis GS; Watts GF; Schultz CJ
J Clin Lipidol; 2018; 12(4):1019-1026. PubMed ID: 29703625
[TBL] [Abstract][Full Text] [Related]
13. The influence of high-density lipoprotein cholesterol on maximal lipid core burden indexing thin cap fibrous atheroma lesions as assessed by near infrared spectroscopy.
Dobrolińska MM; Gąsior P; Wańha W; Pietraszewski P; Pociask E; Smolka G; Wojakowski W; Roleder T
Cardiol J; 2021; 28(6):887-895. PubMed ID: 31909469
[TBL] [Abstract][Full Text] [Related]
14. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study.
Yu MM; Zhao X; Chen YY; Tao XW; Ge JB; Jin H; Zeng MS
Cardiovasc Diabetol; 2023 May; 22(1):121. PubMed ID: 37217967
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention.
Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K
J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480
[TBL] [Abstract][Full Text] [Related]
17. The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis.
Kitahara S; Kataoka Y; Miura H; Nishii T; Nishimura K; Murai K; Iwai T; Nakamura H; Hosoda H; Matama H; Doi T; Nakashima T; Honda S; Fujino M; Nakao K; Yoneda S; Nishihira K; Kanaya T; Otsuka F; Asaumi Y; Tsujita K; Noguchi T; Yasuda S
Atherosclerosis; 2021 Apr; 322():1-7. PubMed ID: 33706078
[TBL] [Abstract][Full Text] [Related]
18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
20. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
Räber L; Taniwaki M; Zaugg S; Kelbæk H; Roffi M; Holmvang L; Noble S; Pedrazzini G; Moschovitis A; Lüscher TF; Matter CM; Serruys PW; Jüni P; Garcia-Garcia HM; Windecker S;
Eur Heart J; 2015 Feb; 36(8):490-500. PubMed ID: 25182248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
